Represents the Company’s fifteenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in the United States as a therapeutic generic equivalent for Zometa® as approved by the U.S. Food and Drug Administration. Zoledronic Acid...
Launched 14 critical injectable medicines since Company inception in October 2023 and remains on track to meet target of 25+ products by year-end 2025. Pursuing two-pronged portfolio development strategy to establish strong foundation of critical injectable products while ensuring long-term competitiveness and return on investment. Company to attend the 43rd Annual J.P. Morgan Healthcare Conference....
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced that it will be attending the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025 in San Francisco, CA.
Company to highlight progress over the past year with potential customers and partners. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it will be attending the 2024 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition in New Orleans, Louisiana from December 8-12, 2024. At the...
Represents the Company’s fourteenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Dexmedetomidine Injection, USP in the United States as a therapeutic generic equivalent for Precedex® as approved by the U.S. Food and Drug Administration. Dexmedetomidine Injection, USP...
JEFFERY YORDON Chief Executive Officer Avenacy Pharmaceutical companies play a critical role in ensuring that their medication packaging and labeling are designed to enhance accurate selection, product differentiation, understanding, and adherence in the home and healthcare facility setting with the ultimate goal of reducing the risk of errors and improving patient health outcomes. One of...
Successfully launched 13 products in less than one year. On track to reach goal of 25+ new product launches in first two years of company inception. Growing portfolio comprised of high-quality, FDA approved injectable medications to treat patients in acute care hospitals, outpatient clinics and physician offices. Strengthened leadership with addition of Dr. Patrick Soon-Shiong...
Represents the Company’s thirteenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan® as approved by the U.S. Food and Drug Administration. Metoclopramide Injection, USP...
Dr. Patrick Soon-Shiong joins Jeff Yordon and Kam Phulwani to build injectable drug company following historical success of American Pharmaceutical Partners Company in strong financial position for significant growth and market expansion Dr. Patrick Soon-Shiong brings over 25 years of pharmaceutical industry experience, including successful commercialization of injectable generic drugs Investment made by NantCapital significantly...
Represents the Company’s twelfth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Palonosetron Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for Aloxi® as approved by the U.S. Food and Drug Administration. Palonosetron Hydrochloride Injection,...
Represents the Company’s eleventh product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Prochlorperazine Edisylate Injection, USP in the United States as a therapeutic generic equivalent for COMPAZINE® as approved by the U.S. Food and Drug Administration. Prochlorperazine Edisylate Injection,...
Represents the Company’s tenth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent for Cyklokapron® as approved by the U.S. Food and Drug Administration. Tranexamic Acid Injection,...
Represents the Company’s ninth product launch since inception in October 2023. Avenacy to offer Isoproterenol Hydrochloride Injection, USP in the market-preferred vial presentation. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Isoproterenol Hydrochloride Injection, USP in the United States as a therapeutic generic equivalent for ISUPREL® as approved by...
Represents the Company’s eighth product launch since inception in October 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Magnesium Sulfate in Water for Injection in the United States as approved by the U.S. Food and Drug Administration. Magnesium Sulfate in Water for Injection is...
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Eptifibatide for Injection in the United States as a therapeutic equivalent generic for Integrilin® for Injection (Eptifibatide) approved by the U.S. Food and Drug Administration. Eptifibatide for Injection is indicated for use in acute coronary syndrome (ACS) and...
Sixth product launch in six months underscores Avenacy’s continued business momentum and commitment to providing essential medicines to patients. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Desmopressin Acetate for Injection in the United States as a therapeutic equivalent generic for DDAVP® for Injection (Desmopressin...
Furosemide represents the company’s fifth product launch and third product announced during DCAT Week 2024. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Furosemide for Injection in the United States as a therapeutic equivalent generic for Lasix® for Injection (furosemide) approved by the U.S. Food and...
Company adds two injectable products, Fosaprepitant for Injection and Fulvestrant Injection, to its growing portfolio for the U.S market. Latest progress marks continued momentum following October 2023 launch, with four portfolio products and a growing pipeline. Management to showcase the Company’s portfolio of critical injectable medications and differentiated business model at DCAT Week 2024 from...
Company’s second product to begin shipping to wholesale partners in January. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin...
Company’s first product to begin shipping to wholesale partners in January. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Melphalan Hydrochloride for Injection in the United States as a therapeutic equivalent generic for Alkeran® for Injection (melphalan hydrochloride) approved by the U.S. Food and Drug...
Company to exhibit and host meetings with potential customers and partners in preparation for initiating commercial operations by year-end 2023. SCHAUMBURG, Ill.–(BUSINESS WIRE)–Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it will be attending the 2023 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting & Exhibition in Anaheim, California...
Portfolio focused on high-quality FDA approved products to treat patients in acute care hospitals, outpatient clinics and physician offices; pursuing 25+ new products over next two years. Differentiated business model ensures supply chain resiliency through established manufacturing partner network. Seasoned team with proven track record of launching critical medications includes Jeffrey Yordon, CEO. Company to...
